July - 2022

Jul 30, 2022

Serological biomarkers of type I, III and IV collagen turnover are associated

Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease. Arno R Bourgonje , Marta S Alexdottir , Antonius T Otten , Roberta Loveikyte , Anne-Christine Bay-Jensen , Martin Pehrsson , Hendrik M van Dullemen , Marijn C Visschedijk , Eleonora A M Festen , Rinse K Weersma , Morten A Karsdal , Klaas Nico Faber , Joachim H Mortensen , Gerard Dijkstra Published in June 2022,

IBDENC ENC

Jul 28, 2022

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Millie D Long, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla, Robert McCabe, Benjamin L Cohen, Ryan C Ungaro, Will Harlan, John Hanson, Gauree Konijeti, Steven Polyak, Timothy Ritter, Bruce Salzberg, Jennifer Seminerio, Emily English, Xian Zhang, Puza P Sharma, Hans H Herfarth Published in June 2022, Inflammatory bowel diseases. Abst

IBDENC ENC

Jul 25, 2022

Metabolome Changes With Diet-Induced Remission in Pediatric Crohn’s Disease

M Ghiboub, S Penny, C M Verburgt, R Sigall Boneh, E Wine, A Cohen, K A Dunn, D M Pinto, M A Benninga, W J de Jonge, A Levine, J E Van Limbergen Published in June 2022, Gastroenterology. BACKGROUND & AIMS The Crohn’s disease (CD) exclusion diet (CDED) plus partial enteral nutrition (PEN) and exclusive enteral nutrition (EEN) both induce remission in pediatric CD. CDED+PEN is better tolerated and able to sustain remission. We characterized the changes in fecal metabolites induc

IBDENC ENC

Jul 23, 2022

Composition and Stability of the Vaginal Microbiota of Pregnant Women With Inflammatory Bowel

Composition and Stability of the Vaginal Microbiota of Pregnant Women With Inflammatory Bowel Disease. Janet E Hill, Juan-Nicolás Peña-Sánchez, Champika Fernando, Aline C Freitas, Niradha Withana Gamage, Sharyle Fowler Published in June 2022, Inflammatory bowel diseases. Abstract Background Inflammatory bowel disease (IBD) is common in women of childbearing years, and active IBD during pregnancy is associated with increased rates of preterm delivery and low-birth-weight newbo

IBDENC ENC

Jul 21, 2022

Cyclin-dependent Kinase 9 as a Potential Target for Anti-TNF-resistant Inflammatory Bowel Disease

Omer S Omer, Arnulf Hertweck, Luke B Roberts, Jonathan W Lo, Jennie N Clough, Ian Jackson, Eirini D Pantazi, Peter M Irving, Tom T MacDonald, Polychronis Pavlidis, Richard G Jenner, Graham M Lord Published in June 2022, Cellular and molecular gastroenterology and Hepatology. Background & Aims Resistance to single cytokine blockade, namely anti-tumor necrosis factor (TNF) therapy, is a growing concern for patients with inflammatory bowel disease (IBD). The transcription factor

IBDENC ENC

Jul 20, 2022

Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota

Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis. Nia Paddison Rees, Walaa Shaheen, Christopher Quince, Chris Tselepis, Richard D Horniblow, Naveen Sharma, Andrew D Beggs, Tariq H Iqbal, Mohammed Nabil Quraishi Published in May 2022, EBioMedicine Summary Background Faecal microbiota transplantation (FMT) has previously been explored as a treatment for ulcerative colitis (UC) how

IBDENC ENC

Jul 16, 2022

Stringent screening strategy significantly reduces reactivation rates of tuberculosis

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Peeyush Kumar, Sudheer K Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet

IBDENC ENC

Jul 15, 2022

Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review

Jasmijn Z Jagt, Charlotte M Verburgt, Ralph de Vries, Nanne K H de Boer, Marc A Benninga, Wouter J de Jonge, Johan E van Limbergen, Tim G J de Meij Author Notes Published in June 2022, Journal of Crohn's and Colitis. Abstract Background and Aims Paediatric inflammatory bowel disease [IBD] is characterized by altered immunological and metabolic pathways. Metabolomics may therefore increase pathophysiological understanding and could develop into characterization of biomarkers f

Etrolizumab versus adalimumab or placebo as induction therapy

IBDENC ENC

Jul 13, 2022

Etrolizumab versus adalimumab or placebo as induction therapy

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. David T Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D R Higgins, Daniel S Mishkin, Pablo Arrisi, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panés , HIBISCUS Study Group Published in Jan 2022, The lance

IBDENC ENC

Jul 8, 2022

Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case study

Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study. Uday C Ghoshal, Ankur Yadav, Bushra Fatima, Anand Prakash Agrahari, Asha Misra Published in Feb 2022, Indian journal of gastroenterology. Abstract Background Though small intestinal bacterial overgrowth (SIBO) is known in inflammatory bowel disease (IBD), the data on it are scanty and have limitations. Methods Data on IBD patients undergoing glucose hydrogen breath test (G

IBDENC ENC

Jul 8, 2022

Ultrasonography in inflammatory bowel disease– So far we are?

Maaser Christian, Maconi Giovanni, Kucharzik Torsten, Allocca Mariangela Published in March 2022, United European gastroenterology journal. Abstract Intestinal ultrasound(IUS) is a non‐invasive and accurate tool to assessinflamma-toryboweldisease.TheECCO‐ESGARguidelinerecommendsthe use of IUS for the assessment of disease activity and complications in Crohn's disease(CD).In addition, an increasing body of evidence suggests the use of IUS as alternative to co-lonoscopy in moni

IBDENC ENC

Jul 5, 2022

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Kevin L Winthrop, Séverine Vermeire, Millie D Long, Julian Panés, Siew C Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y Melmed Published in June 2022, Inflammatory bowel diseases. Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years). Methods

The Mission

Key Opinion Leaders

International

Advisory Board

Initiatives

Discuss a case

Journal Scan

Latest News

Education Hub

Gallery